Literature DB >> 14984629

Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence?

Stephen M Stahl1.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 14984629     DOI： 10.1017/S1461145704004146

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN： 1461-1457            Impact factor:   5.176


× No keyword cloud information.
  10 in total

1.  Does antipsychotic polypharmacy increase the risk for metabolic syndrome?

Authors:  Christoph U Correll; Anne M Frederickson; John M Kane; Peter Manu
Journal:  Schizophr Res       Date:  2006-10-27       Impact factor: 4.939

2.  Trends in adult antipsychotic polypharmacy: progress and challenges in Florida's Medicaid program.

Authors:  Robert J Constantine; Ross Andel; Rajiv Tandon
Journal:  Community Ment Health J       Date:  2010-01-23

Review 3.  A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.

Authors:  William G Honer; Ric M Procyshyn; Eric Y H Chen; G William MacEwan; Alasdair M Barr
Journal:  J Psychiatry Neurosci       Date:  2009-11       Impact factor: 6.186

4.  Trends in psychotropic polypharmacy among youths enrolled in Ohio Medicaid, 2002-2008.

Authors:  Cynthia A Fontanella; Lynn A Warner; Gary S Phillips; Jeffrey A Bridge; John V Campo
Journal:  Psychiatr Serv       Date:  2014-10-31       Impact factor: 3.084

Review 5.  Antipsychotic polypharmacy in schizophrenia: benefits and risks.

Authors:  Thomas R E Barnes; Carol Paton
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

6.  Contrasting Typical and Atypical Antipsychotic Drugs.

Authors:  Herbert Y Meltzer; Erick Gadaleta
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-01-25

Review 7.  Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Authors:  Christoph U Correll; Juan A Gallego
Journal:  Psychiatr Clin North Am       Date:  2012-07-24

Review 8.  Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia.

Authors:  William G Honer; Allen E Thornton; Megan Sherwood; G William MacEwan; Tom S Ehmann; Richard Williams; Lili C Kopala; Ric Procyshyn; Alasdair M Barr
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

9.  Antipsychotic Polypharmacy among Children and Young Adults in Office-Based or Hospital Outpatient Department Settings.

Authors:  Minji Sohn; Meghan Burgess; Mohamed Bazzi
Journal:  Pharmacy (Basel)       Date:  2017-11-23

10.  Drug information update. Unconventional treatment strategies for schizophrenia: polypharmacy and heroic dosing.

Authors:  Bret A Moore; Debbi A Morrissette; Jonathan M Meyer; Stephen M Stahl
Journal:  BJPsych Bull       Date:  2017-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.